CDK5 (Ab-15) Antibody

What is the specificity of CDK5 (Ab-15) Antibody, and what epitope does it recognize?

The CDK5 (Ab-15) Antibody is a polyclonal antibody that specifically detects endogenous levels of total CDK5 protein. It is raised against a synthesized non-phosphopeptide derived from human CDK5 around the phosphorylation site of tyrosine 15 (G-T-Y(p)-G-T) . This antibody has been affinity-purified from rabbit antiserum using epitope-specific immunogen chromatography to ensure high specificity . When designing experiments using this antibody, researchers should be aware that it recognizes the region surrounding Tyr-15, which is a key regulatory phosphorylation site of CDK5.

What are the validated applications for CDK5 (Ab-15) Antibody?

The CDK5 (Ab-15) Antibody has been validated for multiple experimental applications:

For optimal results in Western blotting, researchers should include appropriate positive controls such as extracts from Jurkat cells or HepG2 cells, which have been shown to express detectable levels of CDK5 . The antibody has demonstrated reactivity in human, mouse, and rat samples, making it suitable for comparative studies across these species .

How should I optimize Western blot conditions when using CDK5 (Ab-15) Antibody?

For optimal Western blot results with CDK5 (Ab-15) Antibody:

• Sample preparation: Extract proteins using a buffer containing phosphatase inhibitors (especially when studying phosphorylation status), as described in protocols using "25 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 0.1 mM EGTA, 500 mM NaCl, 0.5% Nonidet P-40, and 1 mM dithiothreitol" .

• Protein loading: Load 20-50 μg of total protein per lane.

• Transfer conditions: Use PVDF membrane (preferred over nitrocellulose) for better retention of phosphorylated proteins.

• Blocking: 5% BSA in TBST is recommended over milk for phospho-specific detection.

• Antibody incubation: Dilute antibody in the range of 1:500-1:3000 in blocking buffer and incubate overnight at 4°C for best results.

• Detection method: ECL-based detection systems provide sufficient sensitivity for endogenous CDK5 levels.

• Controls: Include a CDK5 Y15F mutant as a negative control to confirm specificity, as this mutation prevents phosphorylation at the Tyr-15 site .

What are the critical considerations for immunoprecipitation experiments with CDK5 (Ab-15) Antibody?

When performing immunoprecipitation to study CDK5 complexes:

• Cross-linking: Consider cross-linking the antibody to protein A-Sepharose beads using methods such as the Pierce Crosslink IP kit to minimize antibody contamination in the eluate .

• Buffer composition: Use a lysis buffer that preserves protein-protein interactions: "20 mM HEPES (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 1 mM PMSF, 10 μg/ml leupeptin, and 10 μg/ml aprotinin" .

• Co-IP considerations: When studying CDK5-p35 interactions, be aware that phospho-Tyr-15 CDK5 may not be detected in p35-bound fractions, as research indicates phosphorylation occurs primarily on monomeric CDK5 .

• Washing conditions: Wash immunoprecipitates with washing buffer containing "25 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 0.1 mM EGTA, 500 mM NaCl, 0.5% Nonidet P-40, and 1 mM dithiothreitol" five times to reduce background .

• Elution strategy: Use gentle elution conditions to maintain phosphorylation status.

How do I interpret contradictory findings regarding Tyr-15 phosphorylation and CDK5 activation?

The literature contains contradictory findings regarding the role of Tyr-15 phosphorylation in CDK5 activation, presenting a challenge for researchers. To properly interpret your results:

• Context matters: Earlier studies suggested that Tyr-15 phosphorylation activated CDK5-p35, but more recent findings indicate this is not the case . Kobayashi et al. (2014) demonstrated that "phosphorylation at Tyr-15 is not an activation mechanism of Cdk5 but, rather, indicate that tyrosine kinases could activate Cdk5 by increasing the protein amount of p35" .

• Experimental design considerations:

  • Examine phosphorylation in both monomeric CDK5 and CDK5-activator complexes separately

  • Compare phosphorylation status in the presence and absence of activators (p35/p25, p39)

  • Consider using CDK5 mutants (Y15F, Y15E, Y15A) as controls

• Alternative mechanisms: Consider that tyrosine kinases might activate CDK5 indirectly by increasing p35 levels rather than through direct phosphorylation .

• Cell-type specificity: The relationship between Tyr-15 phosphorylation and CDK5 activity may vary between neuronal and non-neuronal cells. In neurons, activation of Fyn tyrosine kinase did not increase Tyr-15 phosphorylation of CDK5 .

What is the relationship between Abl kinase, CDK5-pY15, and neurodegeneration pathways?

Research has revealed complex interactions between Abl kinase, CDK5-pY15, and neurodegeneration:

• Abl-CDK5 signaling axis: Studies indicate that "Abl and p35/p25 cooperate in promoting Cdk5-pY15, which deregulates Cdk5 activity and subcellular localization in Aβ42-triggered neurodegeneration" . This suggests Abl kinase activity is necessary for CDK5 activation in Alzheimer's disease models.

• Temporal dynamics: In Aβ42-induced neurodegeneration:

  • Abl kinase is activated first

  • This leads to CDK5 binding, activation, and translocation

  • In Drosophila models, this process can be p25-independent

  • In mammalian cells, Aβ42 induces conversion of p35 to p25, but this alone is insufficient for CDK5 activation when Abl is inhibited

• Therapeutic implications: Blockade of Abl kinase rescued both Drosophila and mammalian neuronal cells from Aβ42-induced cell death, suggesting a potential therapeutic approach .

• Experimental approach: When designing experiments to study this pathway, consider:

  • Using Abl kinase inhibitors as controls

  • Comparing p35 to p25 ratios across different experimental conditions

  • Examining CDK5 subcellular localization alongside phosphorylation status

  • Including genetic models (e.g., abl mutations) to validate pharmacological findings

How can I reliably measure CDK5 kinase activity in relation to Tyr-15 phosphorylation?

For accurate measurement of CDK5 kinase activity and its relationship to Tyr-15 phosphorylation:

• Immunoprecipitation-based kinase assay: The gold standard approach involves:

  • Immunoprecipitating CDK5 from protein lysates using anti-CDK5 antibody and Protein A/G beads

  • Using histone H1 or other validated substrates in a kinase reaction

  • Measuring incorporation of 32P or using phospho-specific antibodies to detect substrate phosphorylation

• Non-radioactive alternatives:

  • ELISA-based methods that measure phosphorylation of specific substrates

  • Western blotting to detect phosphorylation of endogenous substrates

• Important controls:

  • Include CDK5 inhibitors to confirm specificity

  • Use CDK5 Y15F mutant to determine the contribution of Tyr-15 phosphorylation

  • Compare wild-type and kinase-dead CDK5 to establish baseline activity

• Considerations for phosphorylation status:

  • Remember that "phosphorylation of Cdk5 itself at either Tyr15 or Ser159 may also possibly play a role in regulating Cdk5 activity"

  • Be aware that "phosphorylation of Tyr15 appears to only occur on inactive monomeric Cdk5"

What are the optimal approaches for studying CDK5 (Ab-15) epitope accessibility in different CDK5 complexes?

When investigating epitope accessibility in different CDK5 complexes:

• Sequential immunoprecipitation approach:

  • First immunoprecipitate with anti-p35/p25 antibody

  • Analyze the bound fraction for CDK5 and phospho-Tyr-15 CDK5

  • Immunoprecipitate the unbound fraction with anti-CDK5 antibody

  • Compare phospho-Tyr-15 levels between fractions

• Structural considerations:

  • The CDK5 (Ab-15) epitope may be masked when CDK5 is bound to activators

  • Research has shown that "phospho-Cdk5 at Tyr-15 was not detected in the p35-bound Cdk5"

• Size-exclusion chromatography:

  • Separate monomeric CDK5 from CDK5-p35/p25 complexes based on size

  • Analyze fractions by Western blot using both total CDK5 and phospho-Tyr-15 antibodies

• Cross-linking studies:

  • Use chemical cross-linkers to stabilize protein-protein interactions

  • Analyze complex composition and phosphorylation status simultaneously

How can CDK5 (Ab-15) Antibody be used to investigate neurodegenerative disease mechanisms?

CDK5 (Ab-15) Antibody is valuable for investigating neurodegenerative mechanisms:

• Alzheimer's disease studies:

  • Monitor changes in CDK5 Tyr-15 phosphorylation in response to Aβ42

  • Compare phosphorylation patterns between healthy and diseased brain tissues

  • Investigate the relationship between Abl activation and CDK5-pY15 levels

• Therapeutic screening:

  • Evaluate CDK5 inhibitors that specifically target the CDK5/p25 complex

  • Screen compounds that may affect Tyr-15 phosphorylation as a potential intervention

  • Assess the effects of peptide inhibitors like "Cdk5i," a 12-amino-acid peptide that "binds to the Cdk5/p25 complex, interferes with p25 binding to Cdk5, and lowers Cdk5/p25 kinase activity"

• Translational models:

  • Use in both rodent models and human tissue samples

  • Apply in "repetitive rotational head trauma in rodents" models to study traumatic brain injury

  • Compare findings between species to validate disease mechanisms

• Experimental design considerations:

  • Include both acute and chronic neurodegenerative models

  • Examine regional differences in CDK5 phosphorylation within the brain

  • Consider co-staining with markers of neuronal damage or death

What methodological approaches can resolve discrepancies in CDK5-pY15 detection in neurodegenerative disease samples?

To address discrepancies in CDK5-pY15 detection in disease samples:

• Antibody validation strategy:

  • Confirm antibody specificity using Y15F mutants as negative controls

  • Compare results from multiple anti-phospho-Tyr-15 antibodies (e.g., those from Abcam, Santa Cruz, Cell Signaling)

  • Include phosphatase treatment controls to confirm phospho-specificity

• Sample preparation optimization:

  • Preserve phosphorylation status by including phosphatase inhibitors immediately upon tissue collection

  • Consider rapid post-mortem collection to minimize degradation

  • Use consistent protocols for all comparative analyses

• Complementary approaches:

  • Combine immunoblotting with mass spectrometry to verify phosphorylation sites

  • Use phospho-proteomics to get a comprehensive view of CDK5 modification states

  • Consider proximity ligation assays to detect specific protein interactions in situ

• Contextual analysis:

  • Examine Tyr-15 phosphorylation in relation to CDK5 activator levels (p35/p25)

  • Assess Abl kinase activity in the same samples

  • Compare findings across different brain regions and disease stages